| Resistance to antibody–drug conjugates S García-Alonso, A Ocaña, A Pandiella Cancer research 78 (9), 2159-2165, 2018 | 193 | 2018 |
| Resistance to the antibody–drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity C Ríos-Luci, S García-Alonso, E Díaz-Rodríguez, M Nadal-Serrano, ... Cancer research 77 (17), 4639-4651, 2017 | 155 | 2017 |
| Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond S García-Alonso, A Ocaña, A Pandiella Trends in cancer 6 (2), 130-146, 2020 | 116 | 2020 |
| Defective cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer MA Sabbaghi, G Gil-Gómez, C Guardia, S Servitja, O Arpí, ... Clinical Cancer Research 23 (22), 7006-7019, 2017 | 95 | 2017 |
| p73 is required for endothelial cell differentiation, migration and the formation of vascular networks regulating VEGF and TGFβ signaling R Fernandez-Alonso, M Martin-Lopez, L Gonzalez-Cano, S Garcia, ... Cell Death & Differentiation 22 (8), 1287-1299, 2015 | 70 | 2015 |
| Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation S García-Alonso, P Mesa, L de la Puente Ovejero, G Aizpurua, ... Molecular cell 82 (18), 3438-3452. e8, 2022 | 40 | 2022 |
| RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression M Sanclemente, P Nieto, S Garcia-Alonso, F Fernández-García, ... Cancer cell 39 (3), 294-296, 2021 | 26 | 2021 |
| Refining early antitumoral drug development A Ocaña, S García-Alonso, E Amir, A Pandiella Trends in Pharmacological Sciences 39 (11), 922-925, 2018 | 26 | 2018 |
| KSR induces RAS‐independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors G Paniagua, HKC Jacob, O Brehey, S García‐Alonso, CG Lechuga, ... Molecular oncology 16 (17), 3066-3081, 2022 | 23 | 2022 |
| Identification of therapeutic targets in ovarian cancer through active tyrosine kinase profiling JC Montero, S García-Alonso, A Ocaña, A Pandiella Oncotarget 6 (30), 30057, 2015 | 21 | 2015 |
| mTOR inhibition and T-DM1 in HER2-positive breast cancer D Casadevall, A Hernández-Prat, S García-Alonso, O Arpí-Llucià, ... Molecular Cancer Research 20 (7), 1108-1121, 2022 | 20 | 2022 |
| Multisite phosphorylation of P-Rex1 by protein kinase C JC Montero, S Seoane, S García-Alonso, A Pandiella Oncotarget 7 (47), 77937, 2016 | 12 | 2016 |
| The WNK1–ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib A Sánchez‐Fdez, S Matilla‐Almazán, JC Montero, S Del Carmen, M Abad, ... Clinical and Translational Medicine 13 (4), e1217, 2023 | 9 | 2023 |
| Altered proTGFα/cleaved TGFα ratios offer new therapeutic strategies in renal carcinoma S García-Alonso, I Romero-Pérez, L Gandullo-Sánchez, L Chinchilla, ... Journal of Experimental & Clinical Cancer Research 40, 1-13, 2021 | 5 | 2021 |
| Supplementary files of the article KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors [Dataset] G Paniagua, HKC Jacob, O Brehey, S García-Alonso, CG Lechuga, ... John Wiley & Sons, 2022 | 1 | 2022 |
| Enfermedad celíaca en población general S García Alonso Enfermedad celíaca en población general, 1999 | 1 | 1999 |
| mTOR inhibition and T-DM1 in HER2-positive breast cancer D Casadevall Aguilar, A Hernández Prat, S García-Alonso, O Arpí Llucià, ... American Association for Cancer Research (AACR), 2022 | | 2022 |
| Identificación de genes responsables de la respuesta a trastuzumab en cáncer de mama HER2 positivo L Díaz-Gil, C Locatelli, A Orive-Ramos, P Tomás-Martín, S García Alonso, ... | | 2018 |
| Anticuerpos conjugados a fármacos frente a receptores erbb: nuevas indicaciones y mecanismos de resistencia S García Alonso | | 2018 |
